NCT05455697View on ClinicalTrials.gov

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 26, 2023

Primary Completion Date

January 5, 2027

Study Completion Date

July 6, 2027

Conditions
Diffuse Large B-Cell LymphomaGrade 3b Follicular LymphomaHigh Grade B-Cell Lymphoma
Interventions
PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Retifanlimab

Given IV

BIOLOGICAL

Rituximab and Hyaluronidase Human

Given SC

BIOLOGICAL

Tafasitamab

Given IV

DRUG

Vincristine

Given vincristine

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

OTHER

Fludeoxyglucose F-18

Undergo FDG-PET/CT

PROCEDURE

Positron Emission Tomography

Undergo FDG-PET

PROCEDURE

Computed Tomography

Undergo FDG-CT

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Polatuzumab Vedotin

Given IV

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER